Explore the details of the Bristol-Myers Squibb Company V. Sciegen Pharmaceuticals, Inc. case under case number 1:23-cv-00393 involving a cause of action for Patent Infringement. Review key information about the parties involved, the patents in question, and the docket entries.

Case Details

Case Number
1:23-cv-00393
Filing Date
Apr 6, 2023
Cause of Action
Patent Infringement
Status
-
Nature of Suit
Patent

The following parties are involved in this case, with their respective legal representatives for the case.

NameRepresented By
Bristol-Myers Squibb Company -
Pfizer Inc. -
ScieGen Pharmaceuticals, Inc. -

Patents Involved in the Case

There is a single patent involved in this case.

Application NumberPatent Number
-US9326945B2

Docket Entries

The Docket Entries section provides a chronological list of all significant filings and court actions in this case.

DateDocket EntryType

Set alerts for critical docket entry

Apr 6, 2023Report to the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) US 9,326,945 B2. (mkr) (Entered: 04/10/2023)PACER Document
Apr 6, 2023Supplemental information for patent cases involving an Abbreviated New Drug Application (ANDA) - Date Patentee(s) Received Notice: 3/4/2023. Date of Expiration of Patent: 2/24/2031.Thirty Month Stay Deadline: 9/4/2025. (mkr) (Entered: 04/10/2023)PACER Document
Apr 6, 2023Notice, Consent and Referral forms re: U.S. Magistrate Judge jurisdiction. (mkr) (Entered: 04/10/2023)PACER Document
Apr 6, 2023COMPLAINT for PATENT INFRINGEMENT filed against ScieGen Pharmaceuticals, Inc. (Filing fee $ 402, receipt number ADEDC-4107837.) - filed by Bristol-Myers Squibb Company and Pfizer Inc. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Civil Cover Sheet) (mkr) (Entered: 04/10/2023)PACER Document
Apr 12, 2023WAIVER OF SERVICE returned executed by Bristol-Myers Squibb Company, Pfizer Inc.: For ScieGen Pharmaceuticals, Inc. waiver sent on 4/10/2023, answer due 6/9/2023. (Farnan, Michael) (Entered: 04/12/2023)PACER Document
Apr 12, 2023MOTION for Pro Hac Vice Appearance of Attorney Robert S. Silver - filed by ScieGen Pharmaceuticals, Inc.. (Rogowski, Patricia) (Entered: 04/12/2023)PACER Document
Apr 13, 2023Disclosure Statement pursuant to Rule 7.1: No Parents or Affiliates Listed filed by ScieGen Pharmaceuticals, Inc.. (Rogowski, Patricia) (Entered: 04/13/2023)PACER Document
Apr 25, 2023MOTION for Pro Hac Vice Appearance of Attorney Amy K. Wigmore, Heather M. Petruzzi, Madeleine Laupheimer, and Andrew J. Danford - filed by Bristol-Myers Squibb Company, Pfizer Inc.. (Farnan, Brian) (Entered: 04/25/2023)PACER Document
Apr 25, 2023STIPULATION of Dismissal by Bristol-Myers Squibb Company, Pfizer Inc.. (Farnan, Brian) (Entered: 04/25/2023)PACER Document
Apr 27, 2023Report to the Commissioner of Patents and Trademarks. (ntl) (Entered: 04/27/2023)PACER Document
Apr 12, 2023Case Assigned to Judge Gregory B. Williams. Please include the initials of the Judge (GBW) after the case number on all documents filed. Associated Cases: 1:23-cv-00392-GBW, 1:23-cv-00393-GBW (rjb)PACER Document
Apr 13, 2023SO ORDERED, re 8 MOTION for Pro Hac Vice Appearance of Attorney Robert S. Silver filed by ScieGen Pharmaceuticals, Inc. Signed by Judge Gregory B. Williams on 4/13/23. (ntl)PACER Document
Apr 13, 2023Pro Hac Vice Attorney Robert S. Silver for ScieGen Pharmaceuticals, Inc. added for electronic noticing. Pursuant to Local Rule 83.5 (d)., Delaware counsel shall be the registered users of CM/ECF and shall be required to file all papers. (mkr)PACER Document
Apr 27, 2023SO ORDERED, re (8 in 1:23-cv-00392-GBW, 10 in 1:23-cv-00393-GBW) MOTION for Pro Hac Vice Appearance of Attorney Amy K. Wigmore, Heather M. Petruzzi, Madeleine Laupheimer, and Andrew J. Danford filed by Pfizer Inc., Bristol-Myers Squibb Company. Signed by Judge Gregory B. Williams on 4/27/23. Associated Cases: 1:23-cv-00392-GBW, 1:23-cv-00393-GBW (ntl)PACER Document
Apr 27, 2023SO ORDERED, re 11 Stipulation of Dismissal filed by Pfizer Inc., Bristol-Myers Squibb Company, ***Civil Case Terminated. Signed by Judge Gregory B. Williams on 4/26/23. (ntl)PACER Document